Model N to Present at the JMP Securities Technology Conference
- 16
Model N, Inc. (NYSE: MODN), the leading provider of cloud revenue management solutions for pharmaceutical, medical device, semiconductor, and high-tech manufacturing companies, today announced that David Barter, CFO, will be presenting at the JMP Securities Technology Conference in San Francisco, CA.
This presentation is scheduled for Monday, February 25, 2019, at 1:00 p.m. PT or 4:00 p.m. ET. A live webcast of the presentation will be accessible from the investor relations page of the Model N website at http://investor.modeln.com/.
About Model N
Model N is the leader in revenue management
solutions. Driving mission critical business processes such as
configure, price and quote (CPQ), contract and rebate management,
business intelligence, and regulatory compliance, Model N solutions
transform the revenue lifecycle from a series of disjointed operations
into a strategic end-to-end process. With deep industry expertise, Model
N supports the complex business needs of the world’s leading brands in
pharmaceutical, medical device, semiconductors and high tech
manufacturing across more than 120 countries, including Pfizer,
AstraZeneca, Sanofi, Gilead, Abbott, Stryker, AMD, Micron, Seagate,
STMicroelectronics, NXP, Sesotec, and Southern States. For more
information, visit www.modeln.com
Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190219005878/en/
- Shareholder Alert: Ademi LLP investigates whether HashiCorp Inc. has obtained a Fair Price in its transaction with IBM
- Marex Group plc Announces Pricing of Initial Public Offering
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- TransAlta Declares Dividends
- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST